Filing Flows › Cartesian Therapeutics (RNAC) › Q1 2026 › vs Q4 2025
Cartesian Therapeutics (RNAC) Q1 2026 vs Q4 2025 (quarter over quarter)
Cartesian Therapeutics's revenue fell $869K (-92%) from $947K in Q4 2025 to $78K in Q1 2026.
Cartesian Therapeutics, Q1 2026: revenue $78K (-93% year over year), net loss $39.2M, operating cash flow −$22.1M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $78K | $947K | −$869K | -92% |
| Net loss | $39.2M | $92.6M | −$53.4M | -58% |
| Costs & expenses | $39.3M | $93.5M | −$54.3M | -58% |
| Operating costs | $26.6M | $79.6M | −$53.0M | -67% |
| Interest & other, net | $12.7M | $13.9M | −$1.3M | -9% |
| Research & development | $19.5M | $14.7M | $4.8M | +33% |
| General & admin | $7.1M | $8.2M | −$1.1M | -13% |
| Operating cash sources | $39.2M | $92.6M | −$53.4M | -58% |
| Depreciation | $600K | $600K | $0 | 0% |
| Share-based compensation | $2.4M | $2.1M | $279K | +13% |
| Working capital & other | $14.0M | $72.1M | −$58.1M | -81% |
| Cash used in operations | $22.1M | $17.7M | $4.4M | +25% |
| Net loss absorbed | $39.2M | $92.6M | −$53.4M | -58% |
Questions
How much did Cartesian Therapeutics's revenue grow quarter over quarter in Q1 2026?
Cartesian Therapeutics's revenue fell $869K (-92%) from $947K in Q4 2025 to $78K in Q1 2026.